PHARMACOEPIDEMIOLOGY OF ANTIBACTERIAL DRUGS FOR PRETERM INFANTS ArticleDyrina K.S., Uvarova E.S., Kutsaya K.O., Zyryanov S.K., Zyryanov S.K.Клинические и теоретические аспекты современной медицины. 2018. 69 с.
HEALTH TECHNOLOGY ASSESSEMENT OF THE FIXED COMBINATION OF INSULIN GLARGINE 100 UI/ML AND LIXISENATIDE IN THE TREATMENT INTENSIFICATION OF DIABETES MELLITUS TYPE 2 ArticleZiryanov S.K., Dyakov I.N.Качественная клиническая практика. 2018. С. 4-13
ТЕРАПИЯ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ: ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ VS. АНТАГОНИСТЫ ЛЕЙКОТРИЕНОВЫХ РЕЦЕПТОРОВ (ОБЗОР ЛИТЕРАТУРЫ) ArticleПереверзев А.П., Зырянов С.К., Ушкалова Е.А., Чельцов В.В.Consilium Medicum. Том 20. 2018. С. 40-44
CLINICAL AND ECONOMIC EVALUATION OF USING FIXED DOSE DUAL BRONCHODILATOR COMBINATION TIOTROPIUMOLODATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ArticleZyryanov S.K., Galatonova Y.A.Медицинский совет. 2018. С. 61-65
PHARMACOECONOMICS EXPEDIENCY OF APPLICATION OF THE COMBINED PREPARATION OF VEZOMNI IN COMPARISON WITH A COMBINATION OF TAMSULOSIN AND SOLIFENACIN IN THE FORM OF MONOPREPARATIONS ArticleZyryanov S.K., Dyakov I.N.Качественная клиническая практика. 2018. С. 35-40
METHODS OF PHARMACOLOGICAL TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION CURRENT APPROACHES TO THE PATIENTS MANAGEMENT ArticleUshkalova E.A., Zyryanov S.K., Zatolochina K.E.Kardiologiia. Том 58. 2018. С. 82-93
PRINCIPLES OF SELECTION AND DOSING OF ANTIBACTERIAL AGENTS IN PATIENTS WITH HEPATIC FAILURE ArticleUshkalova E.A., Zyryanov S.K., Pereverzev A.P.Хирург. 2018. С. 75-88
PHARMACOECONOMIC ANALYSIS OF FLEXIBLE-DOSE ADMINISTRATION REGIMEN OF XEOMINE® IN PATIENTS WITH FOCAL DYSTONIA ArticleCheberda A.E., Belousov D.Yu., Zyryanov S.K.Качественная клиническая практика. 2018. С. 53-65
MODERN MASKS OF INFECTIOUS ENDOCARDITIS ArticleRodoman G.V., Sumedi I.R., Zyryanov S.K., Ivzhits M.A., Kurmashev A.F., Ionidi P.V., Putsman G.A., Kuchuk A.O.Antibiotiki i Khimioterapiya. Том 63. 2018. С. 18-27
PERSPECTIVE FOR USE OF THE RADIONUCLIDE DRUGS IN THE TREATMENT OF MALIGNANT TUMORS IN RUSSIA ArticleZyryanov S.K., Zatolochina K.E.Качественная клиническая практика. 2018. С. 51-57
PHARMACOKINETIC AND PHARMACOGENETIC ASPECTS OF PERSONALIZED ANALGETIC THERAPY WITH FENTANIL TTS IN CLINICAL ONCOLOGY ArticleBobrova O.P., Dyhno Y.A., Shnayder N.A., Petrova M.M., Zyryanov S.K.Siberian Journal of Oncology. Том 17. 2018. С. 94-100
PHARMACOECONOMIC ASSESSMENT OF DUAL BRONCHODILATION THERAPY IN PATIENTS WITH COPD ArticleZyryanov S.K., D'yakov I.N.Pulmonologiya. Том 28. 2018. С. 61-68
GENETICALLY ENGINEERED DRUGS FOR TREATMENT OF BRONCHIAL ASTHMA: RECENT ACHIEVEMENTS ArticleZyryanov S.K., Butranova O.I.Pulmonologiya. Том 28. 2018. С. 584-601
OPTIMIZATION OF EPILEPSY PHARMACOTHERAPY BASED ON A PERSONALIZED APPROACH TO DRUG SAFETY ASSESSMENT ArticleBochanova E.N., Shnayder N.A., Zyryanov S.K., Gusev S.D., Nasyrova R.F.Доктор.Ру. 2018. С. 13-18
GENERIC SUBSTITUTIONS OF ANTIEPILEPTIC DRUGS: IS IT POSSIBLE TO PUT AN END TO THE DISCUSSION? ArticleUshkalova E.A., Zyryanov S.K., Zatolochina K.E.Nevrologiya, Neiropsikhiatriya, Psikhosomatika. Том 10. 2018. С. 75-80
MODERN PROBLEMS OF SURGICAL INFECTIONS OF THE SKIN AND SOFT TISSUES CAUSED BY MRSA, AND THE WAYS OF THEIR SOLUTION ArticleZyryanov S.K., Sychyov I.N.Хирург. 2018. С. 31-43
GCP INSPECTION BY ROSZDRAVNADZOR ArticleBelousov D.Yu., Zyryanov S.K., Kolbin A.S., Karpenko L.I., Rogov E.S.Качественная клиническая практика. 2018. С. 66-76
LEVOFLOXACIN: ANALYSIS OF INFORMATION ON ADVERSE REACTIONS FROM RUSSIAN SPONTANEOUS REPORT DATABASE ArticleZYRYANOV S.K., ZATOLOCHINA K.E., ASETSKAYA I.L.Antibiotiki i Khimioterapiya. Том 63. 2018. С. 46-51
IN VITRO EQUIVALENCE EVALUATION OF BETAHISTINE GENERIC MEDICINAL PRODUCTS AS A TOOL POTENTIALLY DETERMINING THE EFFICACY OF PHARMACOTHERAPY [OTSENKA ÉKVIVALENTNOSTI IN VITRO VOSPROIZVEDENNYKH PREPARATOV BETAGISTINA KAK INSTRUMENTA, POTENTSIAL'NO OPREDELIAIUSHCHEGO ÉFFEKTIVNOST' FARMAKOTERAPII] ArticleZyryanov S.K., Butranova O.I., Ramenskaya G.V., Gildeeva G.N., Shohin I.E.Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. Том 118. 2018. С. 43-48
PHARMACOVIGILANCE SYSTEM IN EURASIAN ECONOMIC UNION ArticleAsetskaya I.L., Zyryanov S.K., Kolbin A.S., Belousov D.Yu.Качественная клиническая практика. 2018. С. 53-72
CLINICO-PHARMACOLOGICAL CHARACTERISTICS OF OPIOID DRUG-DRUG INTERACTIONS IN CANCER PATIENTS WITH CHRONIC PAIN SYNDROME ArticleBobrova O.P., Shnayder N.A., Zyryanov S.K., Dykhno Y.A., Petrova M.M., Nasyrova R.F.Siberian Journal of Oncology. Том 17. 2018. С. 114-122
ФАРМАКОЭКОНОМИЧЕСКОЕ ИССЛЕДОВАНИЕ ПРЕПАРАТОВ, ПРИМЕНЯЕМЫХ ПРИ ЛЕЧЕНИИ ПСОРИАЗА СРЕДНЕТЯЖЕЛОЙ И ТЯЖЕЛОЙ СТЕПЕНИ У ПАЦИЕНТОВ С НЕЭФФЕКТИВНОСТЬЮ БАЗОВОЙ СИСТЕМНОЙ ТЕРАПИИ ArticleЗырянов С.К., Белоусов Д.Ю., Чеберда А.Е.Клиническая фармакология и терапия. Том 27. 2018. С. 91-97
PHARMACOECONOMIC ANALYSIS OF AFATINIB AND GEFITINIB FOR THE TREATMENT OF LUNG CANCER ArticleFedyayev D.V., Zyryanov S.K.Medical Technologies. Assessment and Choice. 2018. С. 68-84
SELECTION OF MODERN P2Y12 INHIBITOR AS A PART OF DUAL ANTITHROMBOTIC THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE: FOCUS ON PRASUGREL ArticleZyryanov S.K., Baibulatova E.A.Лечебное дело. 2018. С. 50-61